A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

CLN2 Disease Clinical Trial

Official title:
A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

Status Approved for marketing

Clinical Trial Summary

- To provide access to BMN 190 to patients with CLN2 disease who cannot participate in a clinical trial.

- To collect additional information on the safety and tolerability of BMN 190 administration in patients with CLN2 disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

CLN2 Disease

Clinical Trial Details

NCT number	NCT02963350
Study type	Expanded Access
Source	BioMarin Pharmaceutical
Contact
Status	Approved for marketing
Phase	N/A

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01907087` - A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease	Phase 1/Phase 2
Completed	`NCT02678689` - A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease	Phase 2
Completed	`NCT02485899` - An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease	Phase 1/Phase 2
Recruiting	`NCT04613089` - Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database